A Trial Measuring ART-123 Ability to Prevent Sensory Neuropathy in Unresectable mCRC Subjects w/Oxaliplatin-based Chemo

Inclusion Criteria: * 18 years of age or older * Unresectable metastatic colorectal cancer; pathologically confirmed adenocarcinoma of the colon or rectum * ECOG performance status of 0 or 1 * The most recent laboratory findings (including for liver and kidney) within 14 days prior to randomization remain within acceptable ranges * Willingness of the patient and the sexual partner to use a highly effective contraceptive method during the course of the study * Able to sufficiently understand the clinical study and give written informed consent Exclusion Criteria: * Prior treatment history with nerve toxic chemotherapeutic agent * Peripheral neuropathy or central nervous system damage * Psychiatric disorder * History of major hemorrhage * High risk of hemorrhage * History of other malignancies * Active ulcer * Patients using anti-coagulants and fibrinolytic drugs * Active Hepatitis B, or known HBs antigen positive * Prior treatment history with thrombomodulin alfa * Administration of another investigational medicinal product within 30 days prior to randomization * Patient is pregnant (positive urine human chorionic gonadotropin) or breastfeeding or intends to get pregnant during the Treatment period * Patients otherwise deemed as inappropriate to participate in the study by the Investigator